Alectinib versus crizotinib as first-line treatment in patients with advanced ALK-mutated non-small cell lung cancer: a Chinese, real-world cohort study - Vienna 2024

Real-word clinical data in lung cancer

Chair(s): Andriani Charpidou, Armin Frille

Session type: Poster session

Alectinib versus crizotinib as first-line treatment in patients with advanced ALK-mutated non-small cell lung cancer: a Chinese, real-world cohort study

Haoran Zhang

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Dont tar them all with the same brush: different grades of visceral pleura invasion in resectable lung adenocarcinomas correlates with aggressive behavior and poor prognostic outcomes.

Stylianos Korasidis

Abstract

A real-world prospective study of nivolumab (NIVO) in patients (pts) with pretreated advanced non-small cell lung cancer (aNSCLC) in Greece and Cyprus Interim analysis results of LUCENCE study

Andriani Charpidou

Poster

Abstract

Challenges in the management of oligometastatic lung cancer

Nidhal Belloumi

Poster

Abstract

Accuracy of radiological assessment of nodal involvement in lung cancer

Kennedy Edwards

Poster

Abstract

Quality of Life in Patients with Advanced NonSmall-Cell Lung Cancer: A Prospective real-world study

Elise M. Beijert

Poster

Abstract

Alectinib versus crizotinib as first-line treatment in patients with advanced ALK-mutated non-small cell lung cancer: a Chinese, real-world cohort study

Haoran Zhang

Poster

Abstract

Quality of Life in Long-Term Survivors with advanced EGFR-Mutated NSCLC

Rolof G.p. Gijtenbeek

Poster

Abstract

Real-world efficacy and safety analysis on three-day continuous intravenous pump infusion of endostar combination therapy for advanced NSCLC

Min Zhang

Poster

Abstract

Lymphocyte changes in peripheral blood of metastatic non-small cell lung cancer patients receiving cryotherapy and immunotherapy

Gediminas Vasiliauskas

Poster

Abstract

Gender Disparities in ICI Therapy: Lung Cancer Patients' Varied Immune Responses

Blerina Resuli

Abstract

Establishment and validation of prognostic nomograms for patients suffering from metastatic pulmonary large cell neuroendocrine carcinoma

Xiaoyun Chen

Poster

Abstract

A meta-analysis on neoadjuvant immunochemotherapy in stage III-IVa (oligometastatic) non-small cell lung cancer

Xiaojie Yang

Abstract

A study on the impact of antibiotics on the efficacy and prognosis of advanced lung cancer patients undergoing immune checkpoint inhibitor therapy

Yufang Xie

Poster

Abstract

Checkpoint Inhibitor-Induced Pneumonitis in Lung Cancer

Qutaiba Shudayfat

Poster

Abstract

Efficacy and safety of concurrent chemoradiotherapy with carboplatin and nanoparticle albumin-bound paclitaxel.

Osamu Kanai

Poster

Abstract

The impact of dietary selenium on all-cause mortality in lung cancer: insights from the national health and nutrition examination survey

Chih-hao Chang

Poster

Abstract

Characteristics of NSCLC patients: predictors of 5-year survival from a nationwide cohort study

Anja Gouliaev

Poster

Abstract

CPET vs PFTs for lung cancer surgery: which is a better indicator of pre-surgical functional status?

Thomas Simon Fitzmaurice

Poster

Abstract

D-Dimer Levels in Lung Adenocarcinoma as a predictor of Chemotherapy Response Based on RECIST

Andreas Infianto

Poster

Abstract

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}